Single-product dependence
Revenue and enterprise value are tied to VYKAT XR adoption and durability.
- Scope
- VYKAT XR
- Materiality
- high
Soleno Therapeutics Inc
Soleno Therapeutics Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for rare diseases. Its lead product is VYKAT XR (diazoxide choline) extended-release tablets, an oral treatment for hyperphagia in adults and children with Prader-Willi syndrome, with operations centered in the United States and potential expansion into other major markets.
6,0 %
98,6 %
11,0 %
5.80
5.55
| % | |
|---|---|
| Commercial pharmaceutical product | 100% VYKAT XR prescription sales for hyperphagia in Prader-Willi syndrome. |
| Drug development pipeline | 0% Research and regulatory work supporting future rare-disease therapeutics. |
| Patient access and support services | 0% Education, financial assistance, and onboarding support via SOLENO ONE. |
The company sells primarily to specialty pharmacy channels that dispense VYKAT XR pursuant to physician prescriptions...
- Specialty pharmacy channelprimary
Buys VYKAT XR and dispenses it to patients under prescription; critical for commercialization.
- Physicians and prescribersprimary
Recommend and prescribe VYKAT XR for eligible PWS patients based on clinical need.
- Patients with Prader-Willi syndromeprimary
Use the therapy to address hyperphagia and related disease burden.
- Payers and reimbursement decision-makerssecondary
Influence access through formulary placement, coverage, and patient out-of-pocket cost.
- Caregivers and patient advocatessecondary
Support treatment initiation, adherence, and navigation of access programs.
Soleno is headquartered in Redwood City, California and conducts its core commercial and operational activities in the...
- •Headquartered in Redwood City, California
- •Primary commercial market is the United States
- •API stored at third-party facilities in the U.S.
- •U.S. CMOs manufacture, package, and label VYKAT XR
- •Europe and Japan are potential future commercialization markets
The company’s strategy is centered on building VYKAT XR into a commercial rare-disease product and expanding physician,...
01
Commercialize VYKAT XR in the U.S.short-term
The company’s value creation depends on physician adoption, patient access, and prescription growth.
02
Build commercial infrastructureshort-term
A rare-disease launch requires targeted sales, medical affairs, and support capabilities.
03
Expand internationally through partners or direct entrymedium-term
Ex-U.S. markets could broaden the addressable patient base while limiting execution risk through partnerships.
04
Protect supply and manufacturing continuityshort-term
Commercial availability depends on third-party API, CMO, and logistics execution.
Soleno is highly dependent on the commercial success of a single approved product, which concentrates execution,...
Market acceptance and reimbursement risk
Physicians, patients, caregivers, and payers must accept the therapy for commercial success.
- Scope
- U.S. launch
- Materiality
- high
Manufacturing and supply-chain disruption
The company relies on third-party CMOs, 3PLs, and external API storage.
- Scope
- Commercial supply
- Materiality
- high
Intellectual property and competitive pressure
Competing PWS therapies or broader appetite-suppression drugs could limit share.
- Scope
- Prader-Willi syndrome market
- Materiality
- medium
International regulatory and partner execution
Ex-U.S. commercialization depends on later strategic decisions and local approvals.
- Scope
- Europe, Japan, other markets
- Materiality
- medium
Revenue reserves under ASC 606
Can materially change product revenue and gross-to-net deductions
Contingent consideration fair value
Can create volatility in operating expenses and net income
Stock-based compensation
Affects SG&A and R&D expense trends
Fair value of marketable securities and financial instruments
Can affect other income/expense and balance sheet values
SOLIGENIX, INC.
SNGX · Pharmaceutical Preparations
ARTELO BIOSCIENCES, INC.
ARTL · Pharmaceutical Preparations
Iterum Therapeutics plc
ITRMF · Pharmaceutical Preparations
Iterum Therapeutics plc is a biopharmaceutical company focused on developing and commercializing ORLYNVAH™ (sulopenem etzadroxil and probenecid), an oral…
UNITED THERAPEUTICS Corp
UTHR · Pharmaceutical Preparations
United Therapeutics is a U.S.-based biopharmaceutical company focused on therapies for pulmonary arterial hypertension and other serious rare diseases, along with organ manufacturing technologies.
INOVIO PHARMACEUTICALS, INC.
INO · Pharmaceutical Preparations
INOVIO Pharmaceuticals is a clinical-stage biotechnology company developing DNA medicines designed to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases.
Dogwood Therapeutics, Inc.
DWTX · Pharmaceutical Preparations
: 29.4.2026